Loss of Trop2 causes ErbB3 activation through a neuregulin-1-dependent mechanism in the mesenchymal subtype of HNSCC

In head and neck squamous cell cancer (HNSCC), four intrinsic subtypes (or groups) have been identified, and each one possesses a unique biology that will require specific treatment strategies. We previously reported that mesenchymal (group 2) tumors exhibit reduced levels of Trop2 expression. In this study, we investigated the functional role of Trop2 in HNSCC and find that loss results in autocrine activation of the EGFR family member ErbB3 via neuregulin-1. Trop2 localizes to both the cell surface and cytosol of HNSCC cells and forms a complex with neuregulin-1, which is predominantly cytosolic. Inactivation of Trop2 increases the concentration of neuregulin-1 at the cell surface where it is cleaved to activate ErbB3. In primary HNSCC, detection of ErbB3 activation was limited to Trop2 negative tumors. An analysis of the Cancer Genome Atlas (TCGA) HNSCC dataset confirms enrichment for ErbB3 activity in mesenchymal tumors. Notably, Trop2 loss triggers sensitivity to anti-ErbB3 antibodies, which results in reduced proliferation and tumorigenic growth of Trop2 negative HNSCC cancer cells. These results uncover a molecular mechanism by which tumor cells control the amount of cell-surface neuregulin-1 available for cleavage and ErbB3 activation. Moreover, we demonstrate that Trop2 is a potential surrogate biomarker to identify tumors with ErbB3 activation and may therefore respond to anti-ErbB3 therapeutics.

[1]  C. Croce,et al.  Loss of miR-125b-1 contributes to head and neck cancer development by dysregulating TACSTD2 and MAPK pathway , 2014, Oncogene.

[2]  Miles A. Miller,et al.  Regulated ADAM17-dependent EGF family ligand release by substrate-selecting signaling pathways , 2013, Proceedings of the National Academy of Sciences.

[3]  D. Hayes,et al.  The Cancer Genome Atlas: Integrated analysis of genome alterations in squamous cell carcinoma of the head and neck. , 2013 .

[4]  Somasekar Seshagiri,et al.  Oncogenic ERBB3 mutations in human cancers. , 2013, Cancer cell.

[5]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[6]  G. Hampton,et al.  High Heregulin Expression Is Associated with Activated HER3 and May Define an Actionable Biomarker in Patients with Squamous Cell Carcinomas of the Head and Neck , 2013, PloS one.

[7]  Christopher R. Cabanski,et al.  Molecular Subtypes in Head and Neck Cancer Exhibit Distinct Patterns of Chromosomal Gain and Loss of Canonical Cancer Genes , 2013, PloS one.

[8]  Jiaoti Huang,et al.  Regulated proteolysis of Trop2 drives epithelial hyperplasia and stem cell self-renewal via β-catenin signaling. , 2012, Genes & development.

[9]  Andreas Wicki,et al.  Molecular Oncology: Targeted therapies in breast cancer , 2013 .

[10]  Yih-Leong Chang,et al.  TROP2 is epigenetically inactivated and modulates IGF-1R signalling in lung adenocarcinoma , 2012, EMBO molecular medicine.

[11]  P. Humphrey,et al.  Loss of Trop2 Promotes Carcinogenesis and Features of Epithelial to Mesenchymal Transition in Squamous Cell Carcinoma , 2011, Molecular Cancer Research.

[12]  P. Jänne,et al.  Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab , 2011, Science Translational Medicine.

[13]  J. Settleman,et al.  Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers. , 2011, Cancer cell.

[14]  C. Sutherland,et al.  Expression of Trop2 Cell Surface Glycoprotein in Normal and Tumor Tissues , 2011, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[15]  C. Blobel,et al.  A transforming Src mutant increases the bioavailability of EGFR ligands via stimulation of the cell-surface metalloproteinase ADAM17 , 2011, Oncogene.

[16]  P. Johnston,et al.  Oncogenic Kras promotes chemotherapy-induced growth factor shedding via ADAM17. , 2011, Cancer research.

[17]  Dhara N. Amin,et al.  The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics. , 2010, Seminars in cell & developmental biology.

[18]  Charles M. Perou,et al.  Deconstructing the molecular portraits of breast cancer , 2010, Molecular oncology.

[19]  Sheng Zhang,et al.  Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway , 2010, Molecular Cancer.

[20]  J. Grandis,et al.  Targeted Chemotherapy for Head and Neck Cancer with a Chimeric Oncolytic Adenovirus Coding for Bifunctional Suicide Protein FCU1 , 2010, Clinical Cancer Research.

[21]  Birgit Schoeberl,et al.  An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. , 2010, Cancer cell.

[22]  Birgit Schoeberl,et al.  An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. , 2010, Cancer research.

[23]  G. Murphy Regulation of the proteolytic disintegrin metalloproteinases, the 'Sheddases'. , 2009, Seminars in cell & developmental biology.

[24]  Dongsheng Tu,et al.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.

[25]  Peter J. Wild,et al.  HER3 Is a Determinant for Poor Prognosis in Melanoma , 2008, Clinical Cancer Research.

[26]  Yiyu Dong,et al.  Identification of Trop-2 as an oncogene and an attractive therapeutic target in colon cancers , 2008, Molecular Cancer Therapeutics.

[27]  Michael Rasse,et al.  TROP2: a novel prognostic marker in squamous cell carcinoma of the oral cavity , 2008, Modern Pathology.

[28]  C. Perou,et al.  Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. , 2004, Cancer cell.

[29]  Joon-Oh Park,et al.  MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.

[30]  K. Shokat,et al.  Escape from HER family tyrosine kinase inhibitor therapy by the kinase inactive HER3 , 2007, Nature.

[31]  J. Minna,et al.  Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. , 2006, Cancer cell.

[32]  D. Carey,et al.  Neuregulin isoforms in dorsal root ganglion neurons: Effects of the cytoplasmic domain on localization and membrane shedding of Nrg‐1 type I , 2006, Journal of neuroscience research.

[33]  M. Kraus,et al.  Frequent overexpression of multiple ErbB receptors by head and neck squamous cell carcinoma contrasts with rare antibody immunity in patients , 2004, The Journal of pathology.

[34]  M. Lemmon,et al.  ErbB3/HER3 does not homodimerize upon neuregulin binding at the cell surface , 2004, FEBS letters.

[35]  F. Maurer,et al.  The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[36]  David Hardisson,et al.  Molecular pathogenesis of head and neck squamous cell carcinoma , 2003, European Archives of Oto-Rhino-Laryngology.

[37]  J. Smyth,et al.  Neuregulin expression, function, and signaling in human ovarian cancer cells. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[38]  Y. Yarden The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. , 2001, European journal of cancer.

[39]  D. Johnston,et al.  Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  L. Cantley,et al.  The erbB3 gene product is a receptor for heregulin. , 1994, The Journal of biological chemistry.

[41]  D. Goeddel,et al.  Identification of Heregulin, a Specific Activator of p185erbB2 , 1992, Science.

[42]  P. Leder,et al.  Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene , 1988, Cell.

[43]  C. Blobel,et al.  ADAMs: key components in EGFR signalling and development , 2005, Nature Reviews Molecular Cell Biology.